stoxline Quote Chart Rank Option Currency Glossary
  
Aeterna Zentaris Inc. (AEZS)
8.36  0 (0%)    05-28 16:00
Open: 8.36
High: 8.69
Volume: 8,407
  
Pre. Close: 8.36
Low: 8.36
Market Cap: 10(M)
Technical analysis
2024-05-28 3:49:50 PM
Short term     
Mid term     
Targets 6-month :  10.31 1-year :  12.04
Resists First :  8.82 Second :  10.31
Pivot price 8.31
Supports First :  8.15 Second :  7.73
MAs MA(5) :  8.37 MA(20) :  8.23
MA(100) :  7.88 MA(250) :  8.84
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  57.7 D(3) :  57.7
RSI RSI(14): 56.1
52-week High :  12.8 Low :  5.44
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AEZS ] has closed below upper band by 40.9%. Bollinger Bands are 17.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.45 - 8.5 8.5 - 8.53
Low: 8.21 - 8.28 8.28 - 8.33
Close: 8.27 - 8.37 8.37 - 8.45
Company Description

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Headline News

Mon, 27 May 2024
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris - br.ADVFN.com

Mon, 27 May 2024
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Movies UK

Fri, 17 May 2024
Aeterna Zentaris Finalizes Merger Details with Ceapro - TipRanks.com - TipRanks

Fri, 17 May 2024
Aeterna Zentaris Finalizes Merger Details with Ceapro - TipRanks.com - TipRanks

Thu, 16 May 2024
Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.com - Defense World

Tue, 14 May 2024
Aeterna Zentaris: Strong Cash Reserve Amidst Upcoming Merger - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 1 (M)
Held by Insiders 1.21e+006 (%)
Held by Institutions 3.9 (%)
Shares Short 5 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.799e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 285.9 %
Return on Equity (ttm) -24.2 %
Qtrly Rev. Growth 4.5e+006 %
Gross Profit (p.s.) -45.73
Sales Per Share -29.5
EBITDA (p.s.) 0
Qtrly Earnings Growth -13.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -17 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.29
Price to Cash Flow 1.16
Stock Dividends
Dividend 0
Forward Dividend 4080
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android